CRBP
Corbus Pharmaceuticals Holdings, Inc.
$9.38
+0.38 (+4.22%)
At close · Jul 7
Market Cap
$176.94M
Shares
18,527,795
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$9.38
Open$9.09
Day$8.99–9.59
52W$7.12–20.56
Avg vol 30d699K
Short int1.6M · 8.5% float · 3.4d
Short vol35%
Last earningsMay 12, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 12
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−8%
below
Price vs 50-day avg
+2%
above
RSI (14)
58
neutral
MACD trend
Positive
52-week position
17%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+24%
trailing
6-month return
+17%
trailing
YTD return
+15%
this year
Relative strength
+10%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $9 › 200d $10 — 200d above 50d
Institutional flow
Distributing
5 of 106 funds reported for Jun 30 · net -85.2K sh shares
Insider flow
Accumulating
Net +$28.1K over 90 days · 75% sells
Short interest
Rising
8.53% of float · ▲ +3.3% MoM · 3.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
106 holders — mid 3-yr range
Squeeze score
60
elevated · 0–100
Fundamentals
Revenue growth
+98%
Y/Y
EPS growth
−60%
Y/Y
Free cash flow
$-64.5M
Balance sheet
$10.6M
net cash
Quant / Vol
risk profile
Volatility
80%
annualized · 1-yr
Max drawdown
−62%
past year
ATR
6.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
Next earnings call
Aug 15, 2026
Est · unconfirmed
· in 5 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 12, 2026
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−8%
Bearish
Price vs 50-day avg
+2%
Bullish
RSI (14)
58
Neutral
MACD trend
Positive
Bullish
52-week position
17%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $9 › 200d $10 — 200d above 50d
Institutional flow
Distributing
5 of 106 funds reported for Jun 30 · net -85.2K sh shares
Insider flow
Accumulating
Net +$28.1K over 90 days · 75% sells
Short interest
Rising
8.53% of float · ▲ +3.3% MoM · 3.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
106 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $7
Now $9 · 17%
52-wk high $21
vs 200-day avg -8%
vs 50-day avg +2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CRBP
this stock
Corbus Pharmaceuticals Holdings, Inc.
|
$176.94M | +15.2% | +97.6% | — | 8.5% |
|
ONC
BeOne Medicines Ltd.
|
$446.53B | +1.7% | +22179.2% | 908.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$132.55B | +15.2% | +46.2% | 31.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.90B | -12.3% | +20.8% | 16.5 | 3.2% |
|
ARGX
Argenx SE
|
$57.20B | +8.8% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CRBP | +4.5% | +24.1% | +17.4% | +0.0% | +15.2% |
| SPY | +0.9% | +1.4% | +7.6% | +0.1% | +9.7% |
| vs SPY | +3.5% | +22.7% | +9.8% | -0.1% | +5.6% |